心脏收缩度调制:从分子模式到心力衰竭子组的量身定制治疗
Nicola Pierucci1, Andrea D'Amato2, Francesca Fanisio3
1Department of Cardiovascular, Respiratory, Nephrological, Anesthesiologic and Geriatric Sciences, Sapienza University of Rome, Rome, Italy - npierucci@gmail.com.
Minerva cardiology and angiology
|November 20, 2024
概括
心脏收缩性调制 (CCM) 疗法可以改善心力衰竭症状,减少住院治疗,而不会增加氧气需求. 这种创新的治疗方法为特定的心力衰竭患者提供了新的选择.
科学领域:
- 心脏病学 心脏病学
- 生物医学工程 生物医学工程
背景情况:
- 心脏收缩度调制 (CCM) 在肌细胞绝对耐火期内利用非刺激信号.
- 通过临床前和临床数据的支持,CCM在不增加心肌氧消耗的情况下显示出无otropic 作用.
研究的目的:
- 审查CCM的病理生理学证据.
- 突出CCM在针对特定患者小组量身定制的心力衰竭治疗中的作用.
主要方法:
- 关于CCM的临床前动物研究和随机临床试验的审查.
- 分析CCM对与心力衰竭,循环和收缩机械相关的基因表达的影响.
主要成果:
- CCM可以逆转心力衰竭中的胎儿基因编程,并调节关键的心脏基因.
- 临床试验表明,CCM在减少心力衰竭住院和改善患者结果方面是安全有效的.
- CCM是心力衰竭患者的可行选择,喷射分数为25-45%,QRS持续时间<130毫秒,不适合CRT.
结论:
- 作为特定心力衰竭患者子组的额外疗法,CCM显示出前景.
- 需要进一步的研究来优化CCM在量身定制的心力衰竭管理.
- 研究CCM患者的位和预后分层的多模式成像是至关重要的.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
Heart Failure Drugs: Inotropic Agents
521
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
521
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
Pathophysiology of Cardiac Performance
566
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
566
Heart Failure Drugs: Diuretics
343
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
343


